Titan Pharma gains more media attention

NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers.

As an implantable version of oral buprenorphine, which is a drug designed to ease withdrawal symptoms, FDA-approved Probuphine is a new hope for those caught in the fight of their lives in the epidemic that is sweeping America.

Titan’s marketing partner, closely-held Braeburn Pharmaceuticals, is currently training healthcare providers on the insertion and removal of the four match-stick size Probuphine rods, which are implanted under the upper arm and designed to release a steady state of buprenorphine over a period of six months.

A copy of the NBC News report can be read here.

Separately, Titan will join the U.S. broad-market Russell 3000 Index and the Russell Microcap Index when the indexes undergo their annual rebalance after U.S. markets close on June 24.

Each June, the entire family of Russell U.S. and Russell Global Indexes are realigned and recalibrated to reflect market changes in the past year. This year, there will be 184 additions to and 133 deletions from the broad Russell 3000 Index.

In a statement, Ron Bundy, CEO North America Benchmarks, FTSE Russell, said the annual reconstitution is a “significant event for the U.S. equity market, closely watched by market participants and an extremely important part of maintaining the integrity and relevance of our leading set of US benchmarks.”